ArticleThe oncologist2026
Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reply: chemotherapy for invasive papillary carcinoma: survival benefit or patient selection?The oncologist · 2026Article
- Chemotherapy for invasive papillary carcinoma: survival benefit or patient selection?The oncologist · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInvasive papillary breast cancer (IPC) is a rare cancer known to have a better prognosis than other breast cancers. This study aimed to explore whether patients with early-stage IPC can benefit from chemotherapy. MATERIALS AND
methodsIPC cases diagnosed between 2003 and 2021 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method and the Cox proportional hazard model were performed to identify significant prognostic factors. To eliminate selection bias and baseline characteristics, propensity score matching (PSM) was used. The primary endpoints were overall survival (OS) and breast cancer-specific survival (BCSS).
resultsA total of 1892 patients were enrolled, and 273 pairs were screened after PSM. Multivariable analysis showed that age under 50, married status, smaller tumor size, negative lymph node (LN) status, and receipt of surgery, chemotherapy or radiotherapy were independently associated with better OS. After PSM, patients receiving chemotherapy had significantly improved OS (P = .012), while BCSS showed no significant difference (P = .099). After stratified by tumor size and LN status, chemotherapy could significantly improve the OS of patients with LN-negative IPC with tumors ≥ 2.0 cm (P < .001). Among the patients with grade III or undifferentiated diseases, the OS of the chemotherapy group was significantly better than that of the non-chemotherapy group (P < .001).
conclusionsFor patients with LN-negative IPC with tumor ≥ 2.0 cm and patients with grade III or undifferentiated disease, chemotherapy significantly improved OS. Future randomized controlled trials are expected to validate the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.